Florida’s CS/CS/SB 1768 does not just regulate how physicians perform non-FDA-approved stem cell therapy. It regulates how they advertise it. The statute requires a specific notice in every advertisement, and that requirement sits on top of, not instead of, the Federal Trade Commission’s rules on health claims and testimonials and the advertising policies of Google and Meta. This post breaks down what a Florida physician must include in stem cell advertising and how the state, federal, and platform layers interact.
TLDR: Florida SB 1768 (Chapter 2025-185) requires a specific statutory notice in any advertisement for stem cell therapy, sized no smaller than the largest type used in the ad. That state requirement does not displace federal rules: the FTC requires competent and reliable scientific evidence for health claims and disclosure of material connections and atypical results in testimonials, and Google and Meta both prohibit ads for unapproved or experimental treatments. Compliant advertising avoids outcome and cure language entirely. Banking adipose tissue does not enroll a patient in therapy and does not guarantee any future eligibility, access, or benefit.
Important Disclaimer: Save My Fat does not provide FDA-approved treatments or cures for any disease. Banking adipose tissue today does not guarantee eligibility, access, or clinical benefit from any future therapy, clinical trial, or medical program. No adipose-derived stem cell product currently holds FDA approval for the conditions discussed in this article. All content is for educational purposes only and does not constitute medical advice. Patients must consult their own licensed healthcare professionals regarding all medical decisions.
The fastest way for a compliant clinical practice to attract a regulator’s attention is through its marketing. A consent form sits in a chart; an advertisement sits in public, indexed and screenshot-able. Florida physicians offering services under SB 1768 should treat advertising review as a distinct compliance function, because three different rule sets apply to the same banner ad at the same time.
The Advertising Requirement Under SB 1768
A physician who conducts stem cell therapy under Section 458.3245 or 459.0127 must include the following notice in any form of advertisement:
“THIS NOTICE MUST BE PROVIDED TO YOU UNDER FLORIDA LAW. This physician performs one or more stem cell therapies that have not yet been approved by the United States Food and Drug Administration. You are encouraged to consult with your primary care provider before undergoing any stem cell therapy.”
The statute sets a prominence standard rather than a fixed point size: the notice must be clearly legible and in a type size no smaller than the largest type size used in the advertisement. This is a relative rule, and it has a practical consequence many practices miss. If your ad’s headline runs at 48-point, the notice cannot drop below 48-point. You cannot bury the disclosure in fine print under a large promotional headline; the statute forces the disclosure to scale with your loudest text. The requirement applies in any form of advertisement, which reasonably encompasses websites, social media, paid search, print brochures, email campaigns, and video. For non-text formats, how a “type size no smaller than the largest type size” rule applies to spoken or video content is exactly the kind of implementation question to confirm with healthcare marketing counsel before you run the campaign.
The FTC Layer
The state notice does not satisfy federal advertising law. The FTC’s Health Products Compliance Guidance sets the substantiation standard: a health-benefit claim must be supported by competent and reliable scientific evidence before it is made, not after. For non-FDA-approved regenerative products, that standard is difficult to meet for most efficacy claims, which is the core reason compliant advertising stays away from benefit and outcome statements altogether.
The FTC’s Rule on the Use of Consumer Reviews and Testimonials adds a second layer that catches practices off guard. If you feature patient testimonials or before-and-after references, you must disclose material connections, meaning any paid relationship, staff, family, or other incentive, and you must address typicality. If a featured result is not what a typical patient experiences, that has to be clear. The rule on testimonials also targets fabricated or purchased reviews, which carry civil penalty exposure. The takeaway for a stem cell practice: a glowing testimonial without a material-connection disclosure and a typicality statement is a federal problem regardless of what Florida law says.
What Google and Meta Allow
Platform policy is the third layer, and it is often the most restrictive. Google’s healthcare and medicines advertising policy prohibits the promotion of speculative or experimental medical treatments, a category that includes unapproved stem cell therapies. Meta applies comparable restrictions on ads for unapproved treatments. What both generally allow is educational content that does not make treatment claims, and consultation calls-to-action that do not promise results.
The critical point: the SB 1768 notice does not override platform policy. Adding the Florida disclosure to a Google ad does not make an otherwise-prohibited stem cell treatment ad acceptable to Google. You must satisfy both. In practice this means most paid promotion in this space is limited to educational or consultation-oriented messaging, with treatment claims removed entirely.
Compliant vs. Non-Compliant Ad Copy
The table below contrasts copy that fails one or more of the three layers with a compliant alternative. The compliant column assumes the SB 1768 notice is also present at the required type size.
| Non-Compliant | Why It Fails | Compliant Alternative |
|---|---|---|
| “FDA-approved stem cell therapy for knee pain” | False FDA-approval claim; the therapy is not FDA-approved for this indication | “Stem cell therapy for orthopedic conditions, performed under Florida SB 1768. [Statutory notice]” |
| “Our patients see real results, every time” | Outcome guarantee; FTC substantiation failure | “Schedule a consultation to discuss whether this option may be appropriate for your condition” |
| “Stem cells for chronic pain that work where nothing else has” | Implied efficacy claim without competent and reliable evidence | “Some clinicians use stem cell therapy for pain management. Individual results vary. [Statutory notice]” |
| “Safer than surgery, no risks” | Absolute safety claim; unsubstantiable | “Like any medical procedure, stem cell therapy carries risks and benefits to discuss with your physician” |
| Patient testimonial with no disclosure | Violates the FTC testimonials rule | Same testimonial with: “Individual results vary and may not be typical. [Material connection disclosed if applicable.]” |
Social Media Compliance
Social content that promotes a specific service is advertising, full stop. An Instagram reel, a TikTok video, or a YouTube clip about your stem cell offering is subject to the same SB 1768 notice expectation and the same FTC rules as a print ad. Two failure modes are specific to social. First, comments and replies create exposure: confirming someone is a patient or describing their clinical outcome in a public reply implicates both FTC testimonial rules and patient privacy. As a HIPAA matter, never confirm in a public reply that any individual is a patient. Second, organic-looking content from staff or affiliates without disclosure can be treated as undisclosed endorsement. Whether and how the SB 1768 notice applies to a given piece of social content is a question for counsel, but the conservative posture is to treat any service-promoting post as an advertisement.
The broader market context for why physician interest in this area has grown is covered in the overview of the regenerative medicine market for physicians, and the foundational case for adding banking specifically is in the discussion of why physicians add adipose banking. Neither is a substitute for a compliance review of your actual ad copy.
Building a Compliant Marketing Review Process
A pre-publish checklist keeps marketing decisions out of individual judgment and into a repeatable workflow. Before any content goes live, confirm: it contains no outcome, disease-claim, or guarantee language; if it references stem cell therapy for a specific condition, that condition is within the orthopedic, wound care, or pain management scope the statute authorizes; the SB 1768 notice is present at the required type size; any testimonial carries typicality and material-connection disclosures; and the content has been reviewed by qualified healthcare marketing counsel. Patients researching providers are increasingly aware of warning signs, and the contrast between compliant and predatory marketing is the subject of the guide on spotting fake stem cell clinics.
Frequently Asked Questions
Does adding the SB 1768 notice make my Google ad compliant?
No. The state notice and platform policy are independent. Google prohibits ads for speculative or experimental treatments regardless of any state disclosure. You must satisfy Google’s policy and the Florida notice requirement separately.
Can I use patient testimonials in my advertising?
Only with FTC-required disclosures. You must disclose material connections and address typicality, and you must not confirm anyone’s patient status in a public forum. Many practices avoid testimonials entirely because the disclosure burden is significant and the privacy risk is real.
What type size does the SB 1768 notice require?
There is no fixed point size. The notice must be no smaller than the largest type size used in that advertisement, and clearly legible. If your headline is large, the notice must match it.
Key Takeaways
Advertising a stem cell practice in Florida is a three-layer problem, and clearing one layer does not clear the others. SB 1768 forces a specific notice, sized to your largest text, into every ad. The FTC independently requires that any health claim rest on competent and reliable scientific evidence before publication and that testimonials disclose connections and atypical results. Google and Meta independently prohibit ads for unapproved or experimental treatments. The intersection of those three rule sets leaves a narrow compliant lane: educational and consultation-oriented messaging, no outcome or cure claims, the statutory notice present, and testimonials either fully disclosed or omitted. A standing pre-publish review, run by counsel rather than by clinical staff, is the only durable way to stay inside that lane.
Save My Fat operates as a tissue preservation service, not a medical practice or treatment provider. Stem cell and regenerative medicine regulations vary by state, including specific informed-consent and disclosure requirements in Florida, Utah, and Nevada governing tissue and stem cell services. Banking adipose tissue does not connect patients to any treatment pathway, and any future use depends on FDA regulatory status, physician guidance, and the availability of approved or investigational pathways at that time.
Physicians weighing how a compliant banking model fits their practice can contact Save My Fat to discuss the operational side. Service and processing details are available at https://savemyfat.com/pricing/.
Save My Fat partners with L2 Bio for laboratory processing and storage.
This article is for educational purposes only and does not constitute medical or legal advice. Legal and medical review including neurology and neurosurgery input is required before publication. Please consult your neurologist or neurosurgeon before making any decisions about neurologic treatment or research participation.
